Summary
Global Markets Direct’s, ‘Retinal Vein Occlusion - Pipeline Review, H1 2016’, provides an overview of the Retinal Vein Occlusion pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion
- The report reviews pipeline therapeutics for Retinal Vein Occlusion by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Retinal Vein Occlusion therapeutics and enlists all their major and minor projects
- The report assesses Retinal Vein Occlusion therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Retinal Vein Occlusion
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Retinal Vein Occlusion pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Aerpio Therapeutics, Inc.
Avalanche Biotechnologies, Inc.
EyeGate Pharmaceuticals, Inc.
Kala Pharmaceuticals, Inc.
Mabion SA
NicOx S.A.
Ohr Pharmaceutical Inc.
Precision Ocular Ltd
pSivida Corp.
ThromboGenics NV
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Retinal Vein Occlusion Overview 7
Therapeutics Development 8
Pipeline Products for Retinal Vein Occlusion - Overview 8
Retinal Vein Occlusion - Therapeutics under Development by Companies 9
Retinal Vein Occlusion - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Retinal Vein Occlusion - Products under Development by Companies 12
Retinal Vein Occlusion - Companies Involved in Therapeutics Development 13
Aerpio Therapeutics, Inc. 13
Avalanche Biotechnologies, Inc. 14
EyeGate Pharmaceuticals, Inc. 15
Kala Pharmaceuticals, Inc. 16
Mabion SA 17
NicOx S.A. 18
Ohr Pharmaceutical Inc. 19
Precision Ocular Ltd 20
pSivida Corp. 21
ThromboGenics NV 22
Retinal Vein Occlusion - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
AKB-9778 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
AVA-101 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
dexamethasone acetate - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Drugs for Retinal Diseases - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
fluocinolone acetonide SR - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
loteprednol etabonate - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
NCX-422 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
NCX-434 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ocriplasmin (recombinant) - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ranibizumab biosimilar - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
squalamine lactate - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Retinal Vein Occlusion - Recent Pipeline Updates 53
Retinal Vein Occlusion - Dormant Projects 77
Retinal Vein Occlusion - Discontinued Products 78
Retinal Vein Occlusion - Product Development Milestones 79
Featured News & Press Releases 79
Nov 04, 2015: Alimera Sciences announces late breaking presentation of new ILUVIEN Analysis During Retina Subspecialty day at AAO annual meeting 2015 79
Sep 28, 2015: Alimera Sciences Announces Availability Of Review Paper On Real World Experience With ILUVIEN 79
Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion 80
Apr 23, 2015: ThromboGenics Starts Evaluating JETREA for the Treatment of Retinal Vein Occlusion 81
Aug 11, 2014: Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion 82
Jul 31, 2014: Kala Pharmaceuticals Initiates Phase 2 Clinical Trial to Evaluate LE-MPP (KPI-121) in Patients with Retinal Vein Occlusion and Diabetic Macular Edema 83
Aug 20, 2013: Ohr Pharmaceutical Announces Investigator Sponsored Trial of Squalamine Eye Drops in Retinal Vein Occlusion 83
Dec 26, 2010: Alimera To Hold Conference Call To Discuss Complete Response Letter Regarding NDA For ILUVIEN 84
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 85
Disclaimer 86
List of Tables
Number of Products under Development for Retinal Vein Occlusion, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Retinal Vein Occlusion - Pipeline by Aerpio Therapeutics, Inc., H1 2016 13
Retinal Vein Occlusion - Pipeline by Avalanche Biotechnologies, Inc., H1 2016 14
Retinal Vein Occlusion - Pipeline by EyeGate Pharmaceuticals, Inc., H1 2016 15
Retinal Vein Occlusion - Pipeline by Kala Pharmaceuticals, Inc., H1 2016 16
Retinal Vein Occlusion - Pipeline by Mabion SA, H1 2016 17
Retinal Vein Occlusion - Pipeline by NicOx S.A., H1 2016 18
Retinal Vein Occlusion - Pipeline by Ohr Pharmaceutical Inc., H1 2016 19
Retinal Vein Occlusion - Pipeline by Precision Ocular Ltd, H1 2016 20
Retinal Vein Occlusion - Pipeline by pSivida Corp., H1 2016 21
Retinal Vein Occlusion - Pipeline by ThromboGenics NV, H1 2016 22
Assessment by Monotherapy Products, H1 2016 23
Number of Products by Stage and Target, H1 2016 25
Number of Products by Stage and Mechanism of Action, H1 2016 27
Number of Products by Stage and Route of Administration, H1 2016 29
Number of Products by Stage and Molecule Type, H1 2016 31
Retinal Vein Occlusion Therapeutics - Recent Pipeline Updates, H1 2016 53
Retinal Vein Occlusion - Dormant Projects, H1 2016 77
Retinal Vein Occlusion - Discontinued Products, H1 2016 78
List of Figures
Number of Products under Development for Retinal Vein Occlusion, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Assessment by Monotherapy Products, H1 2016 23
Number of Products by Top 10 Targets, H1 2016 24
Number of Products by Stage and Top 10 Targets, H1 2016 24
Number of Products by Top 10 Mechanism of Actions, H1 2016 26
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 26
Number of Products by Routes of Administration, H1 2016 28
Number of Products by Stage and Routes of Administration, H1 2016 28
Number of Products by Molecule Types, H1 2016 30
Number of Products by Stage and Molecule Types, H1 2016 30
